Journal
EUROPEAN HEART JOURNAL SUPPLEMENTS
Volume 5, Issue A, Pages A43-A48Publisher
OXFORD UNIV PRESS
DOI: 10.1016/S1520-765X(03)90063-0
Keywords
ACE inhibitors; atherosclerosis; cariovascular disease; HOPE; ramipril; SECURE
Categories
Ask authors/readers for more resources
Angiotensin converting enzyme (ACE) inhibitors decrease angiotensin formation, prevent breakdown of bradykinin, and may also act on other peptides of the renin-angiotensin system. Thus, these agents have many effects that can potentially protect the coronary and peripheral vascularature. Which of these theoretical mechanisms account for the clinical benefit observed in The Heart Outcomes Prevention Evaluation (HOPE) trial? While the answer to this question is complex and cannot be fully answered, several potential mechanisms have been explored within HOPE and its substudies. These studies demonstrate that ramipril has potent effects on atherosclerosis progression and plaque stabilization as well as on myocardial structure and function. Ramipril also improves glucose metabolism. These effects are dose-dependent but largely blood pressure independent. (C) 2003 The European Society of Cardiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available